Ten-year results show a single CAR T infusion can keep many patients with aggressive and slow-growing B-cell lymphomas cancer-free, pointing toward true long-term cures.

A study led by a researcher based at King's College London and McMaster University in Canada reveals how CAR-T cell therapy, a treatment that engineers a patient's own immune cells to recognize and ...

Acclaimed actor Sam Neill, famous for his Jurassic Park role, has passed away. His family confirmed his death on Monday, July ...

A new form of CAR T-cell therapy has been designed to find and destroy the cancer-driving stem cells responsible for a group ...

The company’s lead internal program expands its in vivo CAR T clinical pipeline for patients with relapsed/refractory B cell malignanciesFirst ...

CAR T-cell therapy, a revolutionary cancer treatment known as the living drug, has shown remarkable success in combating ...

Advancing a pipeline of in vivo CAR-T product candidates for oncology and immunology applications differentiated by CD7-targeted mRNA/LNP ...

I f your doctor has recommended chimeric antigen receptor (CAR) T-cell immunotherapy for large B-cell lymphoma (LBCL), you’ve likely already tried several standard treatments, and the cancer did not ...

ESLA READ THE FULL ESLA RESEARCH REPORT Business Update ARTEMIS Platform Potential in Treating Extramedullary Disease Extramedullary disease (EMD) remains one of the most significant unresolved ...

CAR T-cell therapy is expected to expand quickly across autoimmune skin diseases following an anticipated regulatory approval that might come as soon as this year.

CAR T-cell therapy shows promise for SCLC, but significant barriers, such as tumor heterogeneity and immunosuppression, must be addressed. Identifying tumor-selective antigens like CDH17, GD2, and ...

Summary: Chimeric Antigen Receptor T-cell (CAR-T) therapy has revolutionized the treatment of liquid blood cancers by engineering a patient’s own immune cells to destroy malignant targets, replicating ...